Adjuvant chemotherapy in patients with uterine carcinosarcoma: a review of clinical outcomes and considerations

References

• Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004Apr;93(1):204–208. PubMed PMID: 15047237eng
   PubMed Web of Science ®Google Scholar
• Matsuzaki S, Klar M, Matsuzaki S, et al. Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021Feb;160(2):586–601. PubMed PMID: 33183764
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Havrilesky L, Moore DT, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol. 2012Oct;127(1):22–26. PubMed PMID: 22727985; eng
   PubMed Web of Science ®Google Scholar
• Page BR, Pappas L, Cooke EW, et al. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? revised staging, endometrial cancer, histology. Int J Gynecol Cancer. 2012May;22(4):593–598. PubMed PMID: 22343970; eng
   PubMed Web of Science ®Google Scholar
• Bansal N, Herzog TJ, Seshan VE, et al. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol. 2008Jul;112(1):64–70. PubMed PMID: 18591309; eng
   PubMed Web of Science ®Google Scholar
• Matsuo K, Nusbaum DJ, Matsuzaki S, et al. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. Gynecol Oncol. 2020Oct;159(1):43–51. PubMed PMID: 32690393; PubMed Central PMCID: PMCPMC7751572. eng
   PubMed Web of Science ®Google Scholar
• Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. a gynecologic oncology group study. Cancer. 1993Feb15;71(4 Suppl):1702–1709. PubMed PMID: 8381710; eng.
   PubMed Web of Science ®Google Scholar
• Crane E, Naumann W, Tait D, et al. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities. Int J Gynecol Cancer. 2020Apr;30(4):480–484. PubMed PMID: 32114514; eng
   PubMed Web of Science ®Google Scholar
• Jenkins TM, Hanley KZ, Schwartz LE, et al. Mismatch repair deficiency in uterine carcinosarcoma: a multi-institution retrospective review. Am J Surg Pathol. 2020Jun;44(6):782–792. PubMed PMID: 31934920; eng
   PubMed Web of Science ®Google Scholar
• Genome Atlas Research N C, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013May2;497(7447):67–73. PubMed PMID: 23636398; PubMed Central PMCID: PMCPMC3704730.
   PubMed Web of Science ®Google Scholar
• Gotoh O, Sugiyama Y, Takazawa Y, et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun. 2019Oct31;10(1):4965. PubMed PMID: 31672974; PubMed Central PMCID: PMCPMC6823358.
   PubMedGoogle Scholar
• Gotoh O, Kiyotani K, Chiba T, et al. Immunogenomic landscape of gynecologic carcinosarcoma. Gynecol Oncol. 2021Feb;160(2):547–556. PubMed PMID: 33298310
   PubMed Web of Science ®Google Scholar
• Sutton G, Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2005Mar;96(3):630–634. PubMed PMID: 15721404; eng
   PubMed Web of Science ®Google Scholar
• Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004Mar1;58(3):786–796. PubMed PMID: 14967435; eng.
   PubMed Web of Science ®Google Scholar
• Kanthan R, Senger JL. Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int. 2011;2011:470795. PubMed PMID: 22007228; PubMed Central PMCID: PMCPMC3189599. eng.
   PubMedGoogle Scholar
• Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008Nov;199(5):536.e1–8. PubMed PMID: 18511017; eng
   PubMed Web of Science ®Google Scholar
• Denschlag D, Ulrich UA. Uterine carcinosarcomas - diagnosis and management. Oncol Res Treat. 2018;41(11):675–679. PubMed PMID: 30317231; eng.
   PubMed Web of Science ®Google Scholar
• Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European organisation for research and treatment of cancer gynaecological cancer group study.Eur J Cancer. 2008 Apr;44(6):808–818. PubMed PMID: 18378136; eng. protocol 55874.
   PubMed Web of Science ®Google Scholar
• Gerszten K, Faul C, Kounelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998Jan;68(1):8–13. PubMed PMID: 9454652; eng
   PubMed Web of Science ®Google Scholar
• Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol. 2001Apr;27(3):282–285. PubMed PMID: 11373106.
   PubMedGoogle Scholar
• Elshaikh MA, Modh A, Jhingran A, et al. Executive summary of the American radium society® appropriate use criteria for management of uterine carcinosarcoma. Gynecol Oncol. 2020May29;158(2):460–466. PubMed PMID: 32475772; eng.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Omatsu K, Ross MS, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017Apr;145(1):78–87. PubMed PMID: 28215838; eng
   PubMed Web of Science ®Google Scholar
• Zhao F, Tan P, Wang C, et al. Effect of adjuvant therapy on the prognosis in stage I/II uterine carcinosarcoma: a meta-analysis. J Obstet Gynaecol Res. 2021Jul;47(7):2473–2480. PubMed PMID: 33913222
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, Rosenshein N, et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a gynecologic oncology group study). Am J Obstet Gynecol. 1989Aug;161(2):309–312. PubMed PMID: 2548382; eng
   PubMed Web of Science ®Google Scholar
• Curtin JP, Blessing JA, Soper JT, et al. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2001Nov;83(2):268–270. PubMed PMID: 11606082
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, Orr JW Jr., et al. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a gynecologic oncology group study. Cancer Treat Rep. 1986Feb; 70(2): 271–274 PubMed PMID: 3948191; eng
   PubMedGoogle Scholar
• McCourt CK, Deng W, Dizon DS, et al. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2017Jan;144(1):101–106. PubMed PMID: 28029447; PubMed Central PMCID: PMCPMC5362250
   PubMed Web of Science ®Google Scholar
• Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983Aug15;52(4):626–632. PubMed PMID: 6344983; eng.
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Schilder J, et al. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2005Aug;98(2):217–221. PubMed PMID: 15975641
   PubMed Web of Science ®Google Scholar
• Fowler JM, Blessing JA, Burger RA, et al. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2002May;85(2):311–314. PubMed PMID: 11972393
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Sill MW, Darcy KM, et al. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2012Nov;127(2):356–361. PubMed PMID: 22796461
   PubMed Web of Science ®Google Scholar
• Campos SM, Brady WE, Moxley KM, et al. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014Jun;133(3):537–541. PubMed PMID: 24594074; PubMed Central PMCID: PMCPMC4360988
   PubMed Web of Science ®Google Scholar
• Edmondson RJ, O’Connell RL, Banerjee S, et al. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: the PARAGON trial (ANZGOG 0903). Gynecol Oncol. 2021Dec;163(3):524–530. PubMed PMID: 34625284
   PubMed Web of Science ®Google Scholar
• Miller BE, Blessing JA, Stehman FB, et al. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2010Aug1;118(2):139–144. PubMed PMID: 20452658.
   PubMed Web of Science ®Google Scholar
• Sutton G, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a gynecologic oncology group study. PubMed PMID: 11063636eng., Gynecol Oncol. 2000 Nov;79(2):147–153.
   PubMed Web of Science ®Google Scholar
• Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study. J Clin Oncol. 2007Feb10;25(5):526–531. PubMed PMID: 17290061eng.
   PubMed Web of Science ®Google Scholar
• Galaal K, van der Heijden E, Godfrey K, et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2013Feb28;2013(2):Cd006812. PubMed PMID: 23450572; PubMed Central PMCID: PMCPMC6457622. eng.
   Google Scholar
• Powell MA, Filiaci VL, Rose PG, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. J Clin Oncol. 2010Jun1;28(16):2727–2731. PubMed PMID: 20421537PubMed Central PMCID: PMCPMC2881851.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Secord AA, et al. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a gynecologic oncology group study. Gynecol Oncol. 2012Sep;126(3):424–427. PubMed PMID: 22634397
   PubMed Web of Science ®Google Scholar
• Takano T, Otsuki T, Tokunaga H, et al. Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan uterine sarcoma group and Tohoku gynecologic cancer unit study. Int J Clin Oncol. 2014Dec;19(6):1052–1058. PubMed PMID: 24395448; eng
   PubMed Web of Science ®Google Scholar
• Hori K, Nishio S, Ushijima K, et al. A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial. J Gynecol Oncol. 2021Jul;32(4):e64. PubMed PMID: 34085798; PubMed Central PMCID: PMCPMC8192238
   PubMed Web of Science ®Google Scholar
• Powell MA, Filiaci VL, Hensley ML, et al. Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: an NRG oncology trial. J Clin Oncol. 2022Jan10; https://doi.org/10.1200/jco.21.02050 PubMed PMID: 35007153; eng.
   Google Scholar
• Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014Nov;24(9 Suppl 3):S55–60. PubMed PMID: 25341582; eng
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015Jun;137(3):581–588. PubMed PMID: 25805398.
   PubMed Web of Science ®Google Scholar
• Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016Jan;27(1):16–41. PubMed PMID: 26634381; eng
   PubMed Web of Science ®Google Scholar
• Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. PubMed PMID: 17822748PubMed Central PMCID: PMCPMC2752331., Gynecol Oncol. 2007 Nov;107(2):177–185.
   PubMed Web of Science ®Google Scholar
• Otsuki A, Watanabe Y, Nomura H, et al. Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese uterine sarcoma group and the Tohoku gynecologic cancer unit. Int J Gynecol Cancer. 2015Jan;25(1):92–97. PubMed PMID: 25347097; eng
   PubMed Web of Science ®Google Scholar
• Garg G, Yee C, Schwartz K, et al. Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis. Gynecol Oncol. 2014May;133(2):242–249. PubMed PMID: 24561247; PubMed Central PMCID: PMCPMC4501483. eng
   PubMed Web of Science ®Google Scholar
• Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study. J Clin Oncol. 1985Sep;3(9):1240–1245. PubMed PMID: 3897471; eng
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French sarcoma group. Ann Oncol. 2013Apr;24(4):1099–1104. PubMed PMID: 23139262
   PubMed Web of Science ®Google Scholar
• Piver MS, Lele SB, Marchetti DL, et al. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol. 1988Aug;38(4):233–239. PubMed PMID: 3045423; eng
   PubMed Web of Science ®Google Scholar
• Hempling RE, Piver MS, Baker TR. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial. Am J Clin Oncol. 1995Aug;18(4):282–286. PubMed PMID: 7625366; eng.
   PubMed Web of Science ®Google Scholar
• Chow S, Chan JK, Kapp DS, et al. Does chemotherapy or radiation benefit surgical stage I uterine carcinosarcoma patients? Am J Obstet Gynecol. 2020Apr;222(4):383–384. PubMed PMID: 31765639; eng
   PubMed Web of Science ®Google Scholar
• Einstein MH, Klobocista M, Hou JY, et al. Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol. 2012Jan;124(1):26–30. PubMed PMID: 22055846; PubMed Central PMCID: PMCPMC3787514
   PubMed Web of Science ®Google Scholar
• Manolitsas TP, Wain GV, Williams KE, et al. Multimodality therapy for patients with clinical stage I and II malignant mixed müllerian tumors of the uterus. Cancer. 2001Apr15; 91(8)1437–1443. PubMed PMID: 11301390; eng
   PubMed Web of Science ®Google Scholar
• Odei B, Boothe D, Suneja G, et al. Chemoradiation versus chemotherapy in uterine carcinosarcoma: patterns of care and impact on overall survival. Am J Clin Oncol. 2018Aug;41(8):784–791. PubMed PMID: 28121642; eng
   PubMed Web of Science ®Google Scholar
• McEachron J, Heyman T, Shanahan L, et al. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma. Int J Gynecol Cancer. 2020Jul;30(7):1012–1017. PubMed PMID: 32447295; eng
   PubMed Web of Science ®Google Scholar
• Menczer J, Levy T, Piura B, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005Apr;97(1):166–170. PubMed PMID: 15790453; eng
   PubMed Web of Science ®Google Scholar
• Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019Jun13;380(24):2317–2326. PubMed PMID: 31189035; PubMed Central PMCID: PMCPMC6948006.
   PubMed Web of Science ®Google Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–1285.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Nishikawa T, Hirakawa A, et al. 813P efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): a multicenter, phase II clinical trial. Ann Oncol. 2021;32:S767.
   Web of Science ®Google Scholar
• Toboni MD, Crane EK, Brown J, et al. Uterine carcinosarcomas: from pathology to practice. Gynecol Oncol. 2021Jul;162(1):235–241. PubMed PMID: 34030871
   PubMed Web of Science ®Google Scholar